Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Taiwan J Obstet Gynecol ; 62(6): 915-917, 2023 Nov.
Article in English | MEDLINE | ID: mdl-38008515

ABSTRACT

OBJECTIVE: Operative hysteroscopy is a common gynecologic procedure, but it carries the risk of complications. Spontaneous small intestine perforation is rare and fatal, especially in young adults. We present a spontaneous small intestine perforation after operative hysteroscopy with mimicking sign of uterine perforation after operation hysteroscopy. CASE REPORT: A 30-year-old nulligravida woman underwent Truclear® hysteroscopic polypectomy in the morning in LMD. She suffered from upper abdominal pain in the afternoon. Subsequently, progressive abdominal distention and imminent shock occurred the next morning. Initially, it was supposed to be a case of uterine rupture with internal bleeding. She was transferred to the emergency department of our hospital. Complete biochemistry data and abdominal CT were performed. The CT revealed pneumoperitoneum and ascites. Emergent laparoscopy was arranged. The abdominal cavity was full of intestinal fluid and the myomatous uterus was intact. The surgeon performed a laparotomy, two sites of spontaneous perforation of the small intestine were detected. The patient underwent laparotomic segmental resection and anastomosis and was discharged 14 days after surgery without incident. CONCLUSIONS: The risk of uterine perforation during hysteroscopy is up to 1.6%. The use of non-thermal intrauterine morcellator device (Truclear®) has been shown to significantly reduce the risk of perforation and thermal injury. As this case highlights, we suspected the possibility of uterine perforation immediately after hysteroscopic surgery. However, it happened to be rare spontaneous perforation of small bowel. The patient recovered well after timely transfer and management. Hysteroscopy is a very common procedure in gynecologic clinics, but even relatively safe intrauterine morcellator devices carry risk of complications. As a healthcare provider, we should beware of any comorbidity, for sometimes it would be catastrophic.


Subject(s)
Laparoscopy , Uterine Perforation , Pregnancy , Female , Humans , Adult , Hysteroscopy/adverse effects , Uterine Perforation/etiology , Uterine Perforation/surgery , Spontaneous Perforation , Laparoscopy/adverse effects , Intestine, Small
2.
J Aerosol Med Pulm Drug Deliv ; 36(4): 162-170, 2023 08.
Article in English | MEDLINE | ID: mdl-37219568

ABSTRACT

Background: The lung dose of nebulized drugs for spontaneous breathing is influenced by breathing patterns and nebulizer performance. This study aimed to develop a system for measuring breath patterns and a formula for estimating inhaled drugs, and then to validate the hypothesized prediction formula. Methods: An in vitro model was first used to determine correlations among the delivered dose, breath patterns, and doses deposited on the accessories and reservoirs testing with a breathing simulator to generate 12 adult breathing patterns (n = 5). A pressure sensor was developed to measure breathing parameters and used along with a prediction formula that accounted for the initial charge dose, respiratory pattern, and dose on the accessory and reservoir of a nebulizer. Three brands of nebulizers were tested by placing salbutamol (5.0 mg/2.5 mL) in the drug holding chamber. Ten healthy individuals participated in the ex vivo study to validate the prediction formula. The agreement between the predicted and inhaled doses was analyzed using the Bland-Altman plot. Results: The in vitro model showed that the inspiratory time to total respiratory cycle time (Ti/Ttotal; %) was significantly directly correlated with the delivered dose among the respiratory factors, followed by inspiratory flow, respiratory rate, and tidal volume. The ex vivo model showed that Ti/Ttotal was significantly directly correlated with the delivered dose among the respiratory factors, in addition to the nebulization time and accessory dose. The Bland-Altman plots for the ex vivo model showed similar results between the two methods. Large differences in inhaled dose measured at the mouth were observed among the subjects, ranging from 12.68% to 21.68%; however, the difference between the predicted dose and inhaled dose was lower, at 3.98%-5.02%. Conclusions: The inhaled drug dose could be predicted with the hypothesized estimation formula, which was validated by the agreement between the inhaled and predicted doses of breathing patterns of healthy individuals.


Subject(s)
Bronchodilator Agents , Nebulizers and Vaporizers , Adult , Humans , Administration, Inhalation , Aerosols , Albuterol , Equipment Design
5.
Entropy (Basel) ; 24(7)2022 Jul 17.
Article in English | MEDLINE | ID: mdl-35885210

ABSTRACT

Based on the examination of the fundamental characteristics of structures, structural health monitoring (SHM) has received increased attention in recent years. Studies have shown that the SHM method using entropy analysis can precisely identify the damaged location of the structure, which is very helpful for the daily inspection or maintenance of civil structures. Although entropy analysis has shown excellent accuracy, it still consumes too much time and too many resources in terms of data processing. To improve the dilemma, in this study, modified multi-scale symbolic dynamic entropy (MMSDE) is adopted to identify the damaged location of the civil structure. A damage index (DI) based on the entropy diagram is also proposed to clearly indicate the damage location. A seven-story numerical model was created to verify the efficiency of the proposed SHM system. The results of the analysis of each case of damage show that the MMSDE curve for the damaged floor is lower than that for the healthy floor, and the structural damage can be correctly diagnosed by the damage index. Subsequently, a scaled-down steel benchmark experiment, including 15 damage cases, was conducted to verify the practical performance of the SHM system. The confusion matrix was used to further evaluate the SHM system. The results demonstrated that the MMSD-based system can quickly diagnose structural safety with reliability and accuracy. It can be used in the field of long-term structural health monitoring in the near future.

6.
Antivir Ther ; 23(1): 77-85, 2018.
Article in English | MEDLINE | ID: mdl-28671553

ABSTRACT

BACKGROUND: Nucleoside/nucleotide analogue (NA) therapy could be life-saving in chronic hepatitis B (CHB) with spontaneous severe acute exacerbation (SAE). We aimed to investigate the ultra-short virological responses to NA. METHODS: We conducted a randomized controlled trial in which CHB patients with spontaneous SAE were randomized to receive lamivudine (LVD) or entecavir (ETV) between July 2012 and April 2016 (ClinicalTrials.gov: NCT01627223). The serum HBV viral loads on day 1 (baseline), 3, 5, 8, 15, 22, 29, 85 and 180 after initiating NA therapy were checked and analysed. RESULTS: In total, 17 patients (7 in LVD and 10 in ETV group) were recruited, and 3 patients (17.7%) died or received liver transplantation due to hepatic failure. The median (IQR) HBV DNA decline on days 3, 5, 8, 15, 22, 29, 85 and 180 were 1.38 (1.09-1.50), 2.36 (1.89-2.58), 3.19 (2.21-3.51), 3.76 (2.54-4.40), 3.43 (2.44-4.75), 4.00 (3.01-5.04), 5.00 (3.61-6.21) and 6.50 (4.12-7.20) log IU/ml, respectively. The baseline characteristics were basically similar between the two groups, and the dynamic changes in HBV DNA were not significantly different between the two groups. Further analysis of the patients with high HBV viral load (>6 log IU/ml) revealed that a similar baseline HBV DNA level in the two groups (LVD versus ETV: median 8.0 [7.5-8.8] versus 7.7 [6.6-8.4] log IU/ml; P=0.45), and the dynamic changes of HBV DNA were very similar. CONCLUSIONS: CHB with spontaneous SAE responded similarly to treatment using either LVD or ETV, with both drugs inducing a rapid decline of HBV viral load.


Subject(s)
Guanine/analogs & derivatives , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Lamivudine/therapeutic use , Viral Load , Adult , Biomarkers , Drug Therapy, Combination , Female , Guanine/administration & dosage , Guanine/therapeutic use , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/epidemiology , Humans , Incidence , Lamivudine/administration & dosage , Male , Middle Aged , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL